Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sun Pharma Chief’s 1% Interest In Natco Sends India’s Grapevine Into M&A Overdrive

This article was originally published in PharmAsia News

Executive Summary

Sun Pharma chairman’s purchase of stock in Natco is not likely to be a deal precursor.

You may also be interested in...

Will The Next Teva Be From India? Global Scale, Product Mix, And A Strong Balance Sheet Can Trigger Big M&As By Indian Pharma

MUMBAI - News reports of Teva Pharmaceutical Industries Ltd. CEO Shlomo Yanai's recent visit to India sparked rumors that the company may have finally set its sights on the Indian market via a joint venture with Cipla Ltd. But even as the world's largest generic company toys with the idea of entering the sub-continent, leading analysts predict that the next Teva - referencing its multi-fold growth in the last six years - could soon emerge out of India

India's Natco Eyes Generic For Celgene's Mega Brand Revlimid; Will REMS Scuttle The Move?

MUMBAI - Although U.S.-headquartered Celgene succeeded last year in preventing India's Dr. Reddy's Labs from conducting bioequivalence studies on its fast-growing multiple myeloma drug Revlimid (lenalidomide) - due to risk management and restricted distribution issues - it may have a much harder fight on its hands now

Indian Investors Turn Cautious On Compliance Concerns

A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts